A real-world analysis of nearly 7000 patients shows GLP-1s are associated with sharply lower death rates at 5 years in ...

A man in his seventies developed fulminant capecitabine toxicity despite normal DPYD screening, revealing a rare variant that standard testing did not detect.

The Digestive and Liver Center of Florida, along with GI Urgent Care of Florida, is dedicated to providing high-quality, ...

A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has ...

GLP-1 receptor agonists like Ozempic and Wegovy may increase survival among patients with colon cancer. | Drug Discovery And Development ...

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) use was significantly associated with a reduced odds of five-year mortality, but this protective effect was found to be statistically significant ...

GLP-1 RAs are associated with a 62% reduction in 5-year mortality in colon cancer patients, especially those with high obesity. The study's findings remained significant after adjusting for ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center shows that a specific subset of mutations ...

In a new study, colon cancer patients on these medications were more likely to make it to the 5-year survival mark than patients not on the drugs. In a new study, colon cancer patients who took GLP-1 ...

An analysis of secondary endpoints showed that GLP-1 agonist users had a significantly lower risk of myocardial or cerebral ...

A study of 6,800 colon cancer patients found those who took Ozempic or Mounjaro were more likely to survive the disease. It may boil down to inflammation.

Colon cancer, also known as colorectal cancer, is one of the most frequent and aggressive cancers. According to the WHO, it ...